In a remarkable testament to Singapore's prowess in biomedical research, the Singapore Eye Research Institute (SERI) has clinched the top spot among non-academic institutions worldwide in ophthalmology according to the prestigious ScholarGPS 2025 rankings. This achievement, announced in late December 2025 and based on research output from 2021 to 2025, positions SERI as the second-best overall institute globally in this critical medical discipline. Ophthalmology, the branch of medicine focused on the diagnosis, treatment, and prevention of eye diseases and disorders, is an area where SERI's contributions have global ripple effects, particularly in Asia where conditions like myopia and diabetic retinopathy are epidemic.
The ScholarGPS ranking evaluates institutions using advanced metrics including total publications, citation impact, and scholarly influence derived from millions of academic records. SERI's dominance underscores its role as the research arm of the Singapore National Eye Centre (SNEC), the national referral centre for ophthalmology, and highlights how integrated clinical-research models can propel scientific excellence.
SERI's Evolution into a Global Ophthalmology Powerhouse
Founded in 1997 by the visionary Professor Arthur Lim, SERI was established as Singapore's dedicated national institute for ophthalmic and vision research. Starting with just five members, it has expanded to over 253 faculty including clinician-scientists, PhD students, and support staff, plus more than 260 adjunct faculty from Singapore's top biomedical hubs. This growth mirrors Singapore's strategic push into biomedical sciences, where government investments have transformed the city-state into a regional research hub.
SERI's affiliations with leading academic institutions like the National University of Singapore's (NUS) Yong Loo Lin School of Medicine and Duke-NUS Medical School foster seamless knowledge exchange. These partnerships enable joint PhD programs, postdoctoral fellowships, and collaborative grants, creating a fertile ground for aspiring researchers. For instance, Duke-NUS's Centre for Vision Research, co-established with SERI and SNEC, bridges translational research from bench to bedside.
Publication-wise, SERI boasts 6,212 scientific papers, ranking first globally in eye publications per capita—ahead of giants like the US, UK, and Japan. It has secured over $489 million in competitive grants, filed 201 patents, and garnered 885 awards, cementing its status as Asia-Pacific's largest eye research institute.
Decoding the ScholarGPS Methodology and SERI's Metrics
ScholarGPS leverages artificial intelligence to analyze over 30 million scholars and 50,000 institutions, going beyond traditional metrics like h-index to incorporate real-time scholarly impact. For ophthalmology over the prior five years, SERI leads non-academic peers with 1,506 publications and 26,380 citations, achieving #1 in the discipline globally and #2 overall.
Lifetime stats paint an even stronger picture: 4,564 publications, 182,755 citations, and dominance in specialties like diabetic retinopathy (#1), dry eye syndrome (#1), and optical coherence tomography angiography (#1 recent). In Scimago rankings, SERI places #14 in research ophthalmology and #8 among hospitals, validating its multifaceted excellence.
- 89.5% of publications in ophthalmology
- Top 10 cited papers exceed 1,000 citations each, focusing on global disease burdens
- 91.9% in medicine field distribution
This data-driven ascent reflects SERI's emphasis on high-impact, clinically relevant work.
Core Research Thrusts: Tackling Asia's Eye Health Challenges
SERI's portfolio targets prevalent Asian eye conditions. Myopia, dubbed the 'epidemic of the 21st century,' sees Singapore as the world's 'myopia capital' with prevalence rates over 80% in young adults. SERI's Myopia Centre pioneers low-dose atropine therapies and environmental interventions, influencing global guidelines.
Diabetic retinopathy (DR), a leading cause of blindness in diabetics, dominates SERI's specialties. Landmark studies project global DR burden to 2045, guiding screening programs. AI integration, via deep learning models, enables automated DR detection from retinal images, validated in large-scale trials.
Other pillars include glaucoma (progression prediction), corneal diseases, dry eye (novel therapies), and digital health innovations like AI for Alzheimer's early detection via retinal scans—a 2024 breakthrough. Explore SERI's ScholarGPS profile for full metrics.
Photo by Harpreet Singh on Unsplash
Star Researchers Powering SERI's Rise
SERI boasts multiple top scholars. Dr. Daniel Shu Wei Ting ranks #2 globally in ophthalmology (2021-2025), pioneering AI for screening. Five SERI clinician-scientists feature in the top 20, including Prof. Seang-Mei Saw (#1 in refractive error) and Prof. Tin Aung (glaucoma expert).
Prof. Jodhbir Mehta, Executive Director, credits team dedication: "This milestone validates our mission to translate research into patient outcomes." Their work exemplifies clinician-scientist models, blending clinical insight with rigorous science.
For academics eyeing Singapore opportunities, SERI's adjunct roles with NUS and Duke-NUS offer pathways. Check higher ed research jobs or postdoc positions for aligned openings.
Impactful Publications Shaping Global Eye Health Policy
SERI's top-cited works include "Global Prevalence of Myopia and High Myopia" (3,354 citations), projecting 2.5 billion myopes by 2050, and glaucoma burden forecasts influencing WHO strategies. These epidemiological masterpieces provide step-by-step projections: baseline prevalence, risk factors (genetics, near-work), interventions (atropine, orthokeratology).
DR-focused papers detail screening protocols, reducing vision loss by 50% in at-risk populations. Real-world case: SERI's AI-DR model deployed nationally, screening millions affordably.
Strategic Partnerships Fueling Innovation
SERI's collaborations amplify impact. The $21 million SONIC 2.0 with Santen (Dec 2025) targets glaucoma compounds and myopia anti-scarring agents, building on SONIC 1.0's 13 projects and patents. Partnerships with Carl Zeiss ($20M for youth/ageing vision) and A*STAR exemplify Singapore's ecosystem.
Government backing via $50M Translational Clinical Research grants underscores commitment. Learn more on SERI's site. For career advice, see how to craft an academic CV.
Career Pathways and Opportunities at SERI and Affiliates
SERI offers PhD programs, Junior Overseas Fellowships, and clinical trials roles, ideal for ophthalmology enthusiasts. Ties to NUS/Duke-NUS mean access to university jobs in vision science.
- PhD in ophthalmic research
- Postdoc in AI/digital health
- Research assistantships in myopia labs
- Collaborative grants with Duke
Singapore's vibrant scene attracts global talent, with competitive salaries and multicultural environment.
Future Horizons: SERI's Roadmap for 2026 and Beyond
Building on rankings, SERI eyes AI expansions, myopia cures, and personalized medicine. SONIC 2.0 aims for two clinical-stage therapies by 2028. Prof. Mehta envisions greater Asia-Pacific leadership amid rising eye disease burdens from ageing and diabetes.
Stakeholder views: Clinicians praise faster translations; policymakers highlight economic gains (eye care market $500B globally). Challenges like talent retention addressed via fellowships.
SERI's Triumph and Its Broader Implications
SERI's #1 ranking elevates Singapore's biomedical stature, inspiring youth into STEM. For professionals, explore higher ed jobs, research jobs, career advice, or university jobs. In Singapore (SG opportunities), this signals booming prospects in eye research.
Actionable insights: Early myopia control, AI screenings—steps anyone can advocate. SERI proves focused investment yields world-leading results.